HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years 1
Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children 2
A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3
HOYA Vision Care (https://www.hoyavision.com/) today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA.
The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes.
Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said 'This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.'
The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4
'Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child.' said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care.
A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3
'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' saidDr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.'
For the abstracts presented at ARVO 2025, please visit https://www.hoyavision.com/visionary-knowlegde/blogs-and-article/conference-arvo-2025/
Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250611607786/en/
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
17-06-2025
- Yahoo
Enterprise Workforce Management Market Analysis Report 2025: Discover Trends in Cloud Adoption and Remote Work Management, and Learn How WFM Solutions Boost Employee Engagement
Explore the evolving Workforce Management (WFM) market in our comprehensive report. and improve CX. Benefit from detailed reviews of key vendors like Aspect, Calabrio, and NICE. Dublin, June 17, 2025 (GLOBE NEWSWIRE) -- The "2025 Workforce Management for the Enterprise" report has been added to offering. This report provides an in-depth analysis of this mature yet evolving market whose continued projected growth is attributable to factors such as increasing adoption of cloud-based solutions, growing demand for remote work management, and the need for productivity improvements and operational efficiency across verticals. A reawakening and transforming sector It's a tremendously opportunistic time in which WFM solutions are now being used to build employee engagement in contact centers instead of being leveraged to boost productivity, as has traditionally been the case. The market is undergoing a transformation now that companies realize that doing business as usual in their contact centers is not enabling them to achieve their goal of improving the customer experience (CX) while reducing operating costs. It's interesting that the WFM segment's reawakening follows closely on the heels of the self-service revolution. As more organizations come to accept that even the best self-service applications are not going to eliminate the need for human agents in contact centers (or employees in enterprises), having tools to retain these vital resources and reduce onboarding costs becomes more important. Detailed and comprehensive coverage The report examines the WFM market, competitive landscape, technology, products, functional capabilities, and the business, servicing, and market trends driving adoption and innovation. The report also analyzes WFM market activity and provides five-year market projections. It features five vendors that offer WFM solutions addressing the resource management needs of today's complex contact center environments: Aspect, Assembled, Calabrio, NICE, and Verint Systems. Bright Pattern is covered at a higher level. The right RFP Q&As to identify the best WFM selection for your organization The report includes detailed side-by-side comparative analyses of 175+ RFP questions and vendor responses to enable end-users seeking a WFM solution to easily compare the most important features for their contact center's success. (Vendor responses have been carefully reviewed and vetted by a team of leading contact center technology and operations experts during in-depth live product demonstrations.) The report's side-by-side comparative analyses provide a wide range of information about the featured solutions' capabilities, including: Omnichannel Forecasting Long-Term Strategic Planning Hiring Management Workspace Allocation Omnichannel Scheduling Agent Self-Service Multinational and Union Requirements Real-Time Adaptive Intraday Management Real-Time Adherence Contact Center and Agent Performance Management Gamification eLearning/Meeting Management Back Office/Branch Key Topics Covered: 1. Executive Summary 2. Introduction 3. Research Methodology3.1 Report Participation Criteria 4. Workforce Management Defined4.1 WFM Product Overview 5. WFM Trends and Challenges5.1 WFM Trends5.2 WFM Challenges 6. WFM Market Innovation6.1 New Features6.2 Emerging Capabilities 7. Art, Science, and AI: Redefining What's Possible in WFM 8. Forward Thinking: Contact Center Forecasting and Strategic Planning for Resource and Capacity Management8.1 Omnichannel WFM Operational Requirements and CX Management8.2 Omnichannel Forecasting8.3 Long-Term Strategic Planning8.4 Hiring Management8.5 Workspace Allocation 9. A Modern Approach to Scheduling9.1 Omnichannel and Multi-Skill Scheduling9.2 Agent Self-Service9.3 Global and Union Requirements 10. Navigating the Unexpected: Tackling Intraday Challenges with Real-Time Solutions10.1 Real-Time Adaptive Intraday Management10.2 Real-Time Adherence10.3 Contact Center and Agent Performance Management10.4 Gamification10.5 eLearning/Meeting Management 11. Back-Office/Branch WFM 12. Workforce Management Market Activity12.1 Validating Market Numbers12.2 WFM Market Share Analysis 13. WFM Adoption Rate 14. Workforce Management Projections 15. Workforce Management Competitive Landscape15.1 Company Snapshot 16. Pricing16.1 Cloud-Based Pricing 17. Company Reports17.1 Aspect17.2 Assembled17.3 Bright Pattern, Inc.17.4 Calabrio17.5 NICE17.6 Verint Systems For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error al recuperar los datos Inicia sesión para acceder a tu cartera de valores Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos Error al recuperar los datos
Business Upturn
13-06-2025
- Business Upturn
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Salt Lake City, United States: Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years 1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children 2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said 'This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future.' The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 'Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child.' said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 'With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent,' saidDr. Vlasak. 'With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations.' For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash
Yahoo
12-06-2025
- Yahoo
HOYA Vision Care Unveils Updates from the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting
Latest evidence from the world's longest running study on myopia management spectacle lenses reinforced the effectiveness of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology in continuing to significantly reduce myopia progression and axial elongation over 8 years1 Findings from the randomized controlled trial, ASPECT, demonstrated that combining 0.025% atropine drops with DIMS spectacle lenses reduces axial elongation in myopic children2 A first-of-its-kind concept trial showed that D.I.M.S. Technology may offer a protective effect against the development of myopia in pre-myopic preschool children and postpone the onset of myopia3 SALT LAKE CITY, June 12, 2025--(BUSINESS WIRE)--HOYA Vision Care ( today announced new clinical evidence from three key clinical studies highlighting the impact of Defocus Incorporated Multiple Segments (D.I.M.S.) Technology. The results were presented as part of the company's 2025 scientific program, Exploring New Frontiers in Myopia Management with MiYOSMART*, at the Association for Research in Vision and Ophthalmology (ARVO) 2025 Annual Meeting in Salt Lake City, Utah, USA. The latest findings from the world's longest-running clinical study on myopia management spectacle lenses showed that continuous DIMS spectacle lens wear demonstrated significantly reduced myopia progression (-1.00D ± 0.41D, p=0.017) and axial elongation (0.42 ± 0.18 mm, p=0.019) consistently for the full 8 years (n=11) of follow-up.1 This evidence demonstrates that wearing MiYOSMART* spectacle lenses continuously and for the long-term may improve myopia management outcomes. Dr. Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care said "This landmark study, featuring the longest follow-up to date for myopia management spectacle lenses, reveals that long-term MiYOSMART use continues to significantly slow myopia progression so that children can enjoy their lives to the fullest. These findings emphasize the life-changing value of long-term adherence, providing crucial information and guidance for Eye Care Professionals and parents committed to protecting children's vision health for the future." The first 12-month data readout from the ASPECT randomized controlled trial demonstrated that combining low-dose 0.025% atropine eye drops with DIMS spectacle lenses stopped myopia progression in around 40% of children.2 The mean change in axial length, a key factor in myopia progression, was significantly lower than in the atropine-only group (0.07 ± 0.16 mm vs 0.18 ± 0.16 mm; p<0.001). The researchers also explored vision-related quality of life (VR-QoL), indicating a trend towards improvement in general vision (p=0.049) and competence (p=0.031) in children using low-dose atropine and DIMS spectacle lens combination treatment.4 "Our findings suggest that combining MiYOSMART spectacle lenses with atropine can unlock even greater outcomes for children with myopia progression – marking a positive step towards more personalized, powerful treatment strategies in myopia management that suit the unique needs of each child." said Dr Natalia Vlasak, Global Head of Medical and Scientific Affairs at HOYA Vision Care. A first-of-its-kind pilot study evaluating DIMS spectacle lenses for pre-myopia management in 5- and 6-year-old children indicated that the DIMS technology may offer a protective effect against the development of myopia in this population. Over nine months, the average cycloplegic spherical equivalent refraction (SER) remained stable with a yearly change of +0.06D compared to -0.15D in a control group. While axial length increased slightly (22.48 mm to 22.64 mm, p<0.01), the choroidal thickness remained stable. These promising initial findings suggest MiYOSMART spectacle lenses may help to prevent myopia development and postpone the myopia onset in pre-myopic preschoolers, laying the groundwork for future research.3 "With myopia rising at an alarming rate worldwide, finding effective strategies to slow its progression have never been more urgent," said Dr. Vlasak. "With these studies, we continue to provide Eye Care Professionals and parents with confidence through evidence for the benefits of MiYOSMART spectacle lenses, both as a monotherapy and in combination treatment. We are proud to deliver on our mission to protect the long-term vision and quality of life for every child through our evidence-backed myopia management innovations." For the abstracts presented at ARVO 2025, please visit Product Disclaimer: *MiYOSMART spectacle lenses have not been approved for myopia management in all countries, including the United States, and are not currently available for sale in all countries. View source version on Contacts Pamela Pedrucci PR, Media and External Comms Director HOYA Vision Care Sign in to access your portfolio
